Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kise or Tyrosine Protein Kise TYRO11 or EPHB4 or EC 2.7.10.1) - Overview
Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kise or Tyrosine Protein Kise TYRO11 or EPHB4 or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kise or Tyrosine Protein Kise TYRO11 or EPHB4 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kise or Tyrosine Protein Kise TYRO11 or EPHB4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Kadmon Corp LLC
VasGene Therapeutics Inc
Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kise or Tyrosine Protein Kise TYRO11 or EPHB4 or EC 2.7.10.1) - Drug Profiles
Small Molecule to Inhibit VEGFR2, TIE 2 and EPHB4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Antagonize EphB4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Antagonize EphB4 Receptor for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kise or Tyrosine Protein Kise TYRO11 or EPHB4 or EC 2.7.10.1) - Dormant Products
Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kise or Tyrosine Protein Kise TYRO11 or EPHB4 or EC 2.7.10.1) - Discontinued Products
Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kise or Tyrosine Protein Kise TYRO11 or EPHB4 or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Kadmon Corp LLC, H1 2020
Pipeline by VasGene Therapeutics Inc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020